Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.

Renuka V IyerBhavana KondaChristos FountzilasSarbajit MukherjeeDwight OwenKristopher AttwoodChong WangOrla MaguireHans MindermanSheryl-Ann SuffrenKaren HicksJohn WiltonRobert BiesDanielle CasucciDiane Reidy-LagunesManisha Shah

Published in: Cancer (2020)

Nintedanib is active in nonpancreatic NETs. The immunosuppressive effect of serotonin should be targeted in future clinical trials.

Keyphrases

neuroendocrine tumors
idiopathic pulmonary fibrosis
clinical trial
interstitial lung disease
current status
double blind
cancer therapy
systemic sclerosis
cross sectional
phase ii
rheumatoid arthritis
open label
randomized controlled trial